Department of Surgery, University of Alabama at Birmingham, Alabama, USA
Department of Surgery, University of Alabama at Birmingham, Alabama, USA.
Oncologist. 2019 Sep;24(9):e828-e834. doi: 10.1634/theoncologist.2018-0424. Epub 2019 Apr 24.
Hyperparathyroidism is both underdiagnosed and undertreated, but the reasons for these deficiencies have not been described. The purpose of this study was to identify reasons for underdiagnosis and undertreatment of hyperparathyroidism that could be addressed by targeted interventions.
We identified 3,200 patients with hypercalcemia (serum calcium >10.5 mg/dL) who had parathyroid hormone (PTH) levels evaluated at our institution from 2011 to 2016. We randomly sampled 60 patients and divided them into three groups based on their PTH levels. Two independent reviewers examined clinical notes and diagnostic data to identify reasons for delayed diagnosis or referral for treatment.
The mean age of the patients was 61 ± 16.5 years, 68% were women, and 55% were white. Fifty percent of patients had ≥1 elevated calcium that was missed by their primary care provider. Hypercalcemia was frequently attributed to causes other than hyperparathyroidism, including diuretics (12%), calcium supplements (12%), dehydration (5%), and renal dysfunction (3%). Even when calcium and PTH were both elevated, the diagnosis was missed or delayed in 40% of patients. For 7% of patients, a nonsurgeon stated that surgery offered no benefit; 22% of patients were offered medical treatment or observation, and 8% opted not to see a surgeon. Only 20% of patients were referred for surgical evaluation, and they waited a median of 16 months before seeing a surgeon.
To address common causes for delayed diagnosis and treatment of hyperparathyroidism, we must improve systems for recognizing hypercalcemia and better educate patients and providers about the consequences of untreated disease.
This study identified reasons why patients experience delays in workup, diagnosis, and treatment of primary hyperparathyroidism. These data provide valuable information for developing interventions that increase rates of diagnosis and referral.
甲状旁腺功能亢进症的诊断和治疗不足,但尚未描述这些不足的原因。本研究旨在确定可通过针对性干预来解决甲状旁腺功能亢进症诊断和治疗不足的原因。
我们从 2011 年至 2016 年在本机构评估甲状旁腺激素(PTH)水平的 3200 例高钙血症(血清钙>10.5mg/dL)患者中随机抽取 60 例,并根据 PTH 水平将其分为三组。两名独立的评审员检查了临床记录和诊断数据,以确定诊断延迟或转介治疗的原因。
患者的平均年龄为 61±16.5 岁,68%为女性,55%为白人。50%的患者的初级保健医生已经发现了≥1 次血钙升高但未进行治疗。高钙血症常归因于甲状旁腺功能亢进症以外的原因,包括利尿剂(12%)、钙补充剂(12%)、脱水(5%)和肾功能不全(3%)。即使钙和 PTH 均升高,仍有 40%的患者被误诊或延迟诊断。对于 7%的患者,非外科医生表示手术没有益处;22%的患者接受了药物治疗或观察,8%的患者选择不看外科医生。只有 20%的患者被转介进行手术评估,他们在看外科医生之前平均等待了 16 个月。
为了解决甲状旁腺功能亢进症诊断和治疗延迟的常见原因,我们必须改进识别高钙血症的系统,并更好地教育患者和医务人员关于未治疗疾病的后果。
本研究确定了患者在原发性甲状旁腺功能亢进症的检查、诊断和治疗中延迟的原因。这些数据为制定提高诊断率和转介率的干预措施提供了有价值的信息。